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Background: Metabolic syndrome (MS) is a cluster of the most dangerous cardiac risk factors and is associated
with high mortality. Ethnic differences in metabolic syndrome (MS) criteria and prevalence rates have been
reported. The purpose of this study was to investigate the MS prevalence among patients with schizophrenia in
Palestine.
Methods: We recruited 250 patients with schizophrenia from 4 psychiatric primary healthcare centers in Northern
Palestine. The MS prevalence was assessed based on National Cholesterol Education Program Adult Treatment
Panel III Adapted criteria.
Results: The overall MS prevalence was 43.6%, with 39% in male and 55.9% in female patients. On average, the
study patients had 2.3 ± 1.3 metabolic abnormalities. Univariate analysis showed that MS was significantly higher
with older age, female gender, longer duration of the illness, smoking, abdominal obesity, high systolic and
diastolic blood pressure, high triglycerides, low HDL-C, and high fasting plasma glucose. Multiple logistic regression
analysis showed that only systolic blood pressure, high triglycerides, high fasting plasma glucose, and low HDL-C
were significant predictors of MS in schizophrenic patients.
Conclusions: MS is common among Arab patients with schizophrenia. Patients with schizophrenia should receive
regular monitoring and adequate treatment of cardio-metabolic risk factors.
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Schizophrenia is a mental disorder that affects approxi-
mately one percent of the various populations through-
out the world [1-3]. Patients with schizophrenia are
reported to have shorter life span compared to the
general population [4-6]. The most commonly reported
cause of excess mortality among patients with schizo-
phrenia is cardiovascular diseases [7,8]. Cardiovascular
morbidity and mortality among patients with schizo-
phrenia has been linked to high prevalence of metabolic
syndrome [9]. Metabolic syndrome (MS), also known as
syndrome X or insulin resistance syndrome is a cluster
of interrelated metabolic risk factors that appear to
directly promote the development of atherosclerotic car-
diovascular disease [10-13]. Furthermore, metabolic
abnormalities not only have an impact on physical health* Correspondence: waleedsweileh@yahoo.com
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reproduction in any medium, provided the orbut also on a poorer quality of life [14], non-compliance
[15] and a lower functional outcome [16].
Three definitions of MS have been proposed by the
National Cholesterol Education Program Adult Treat-
ment Panel III (NCEP ATPIII), the World Health
Organization (WHO) and the International Diabetes
Federation (IDF) [17-19]. Regardless of the criteria, five
factors, are thought to comprise MS—large waist cir-
cumference (WC; as indicator of central obesity), ele-
vated triglycerides (TG), low high-density lipoprotein
cholesterol (HDL-C) concentration, high blood pressure
and elevated fasting plasma glucose. The most com-
monly used definitions for the MS are the NCEP ATPIII,
and the adapted ATP-III A proposed by the American
Heart Association (AHA) following the ADA lowering
of the threshold for impaired fasting glucose to 100 mg/
dl [20,21]. The IDF stressed the importance of waist
circumference, using both more stringent and ethnic-/
race-specific criteria in the definition of MS. Recently,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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representatives held discussions to attempt to resolve
the remaining differences between definitions of meta-
bolic syndrome. Both sides agreed that abdominal obe-
sity should not be a prerequisite for diagnosis but that it
is 1 of 5 criteria, so that the presence of any 3 of 5 risk
factors constitutes a diagnosis of metabolic syndrome
[22].
Recent research on MS in the general population has
indeed provided evidence for the development of eth-
nic-/race-specific criteria [23-25]. Until now, it has
remained unclear to what extent these differences in the
general population are due to genetic factors or cultural
factors such as life style or economic factors. As the
criteria of MS as well as life style and economic factors
are different between ethnic groups, evaluation of the
prevalence of MS in patients with schizophrenia in
different ethnic groups is needed.
Many reports have been published on the prevalence
of the MS in the general population among Arabs in the
Middle East [26-28]. However, reports about the preva-
lence of MS among Arab patients with schizophrenia are
very few. To further investigate the prevalence of meta-
bolic syndrome among Arab patients with schizophrenia,
this study was carried out among a sample of patients
with schizophrenia in Palestine.
Methods
Research design and methods
This is a cross sectional study conducted from August
2011 until February 2012 at governmental primary
healthcare psychiatric centers in Northern West-Bank,
Palestine. All patients attending the psychiatric health-
care centers during the study period with the following
criteria were invited to participate: 1) their age was
above 16 years old, and 2) they were diagnosed with
schizophrenia as defined by DSM-IV. In order to
estimate with sufficient precision the prevalence of MS,
we hypothesized that the prevalence of MS to be 30%.
We calculated the sample size with a 99% confidence
interval and of a 10% width. Based on this, we needed a
sample size at least 100 patients.
On the assessment day, we collected demographic and
clinical information, including current antipsychotic use,
from medical documents of the institutions. The follo-
wing types of information were collected: gender, age,
occupation, marital status, length of psychiatric illness,
antipsychotic medications; waist circumference (WC),
fasting plasma glucose (FPG) measured in mg/dL, and
lipid profile. Focus group discussions were continuously
held between the research team to maintain rational of
the data collection process. Regular evaluations took
place throughout the abstraction period to identify anyproblems in data collection, the interpretation of defini-
tions, and the application of study criteria. Before
commencing data analysis, an extensive series of checks
were performed for data consistency, proper sequences
of data, and an evaluation of missing or incomplete data.
The data collection form was modified by the principal
researchers and the modified version was reviewed by
experts to ensure content and construct validity. Data
from the pre-test evaluation were not included in the
final analysis. Approval to perform the study was
obtained from the Palestinian ministry of health and
the college of Graduate Studies at An-Najah national
University and Institutional Review Board (IRB). Written
consent was obtained from patients.
The antipsychotic use patterns were recorded by the
types and number of administered antipsychotic drugs. As
clozapine and olanzapine have the highest potential to
cause metabolic abnormalities [29,30] and weight gain
[31], we classified the types of antipsychotic drugs into a
clozapine/ olanzapine group and other antipsychotics
group. The number of antipsychotics used was categorized
as monotherapy, currently using only one kind of anti-
psychotic drug, and combination, currently using more
than one kind of antipsychotic. Medical information
regarding the duration of current antipsychotic regimen
or previous antipsychotic usage were not obtained due to
limited related information in their documents. Waist
circumference (WC) was measured using an outstretched
tape meter, without any pressure to the body surface, and
was recorded to the nearest 0.1 cm. The waist measure-
ment was taken with the tape meter in a horizontal plane,
midway between the inferior margin of the ribs and the
superior border of the iliac crest. To avoid inter-subjective
error, all measurements were taken by the same person.
Sitting blood pressure (BP) was performed. Two BP
measurements were made by two nurses in the right arm
after the participant sat and rested for at least 5 min. In
case of difference in BP reading, a third one was carried
out and the average was calculated. For FPG blood
samples were collected from all subjects between 8:00 and
9:00 (a.m.) after 12 h overnight fast. Blood was collected
from an ante-cubital vein punctures and was collected
while subject or client in a sitting position. FPG was deter-
mined using Chemistry kits bought from Human,
Germany. Blood samples were taken in a sitting position
according to the standard protocol and centrifuged within
30 to 45 minutes of collection. Biochemical analysis was
conducted on fasting plasma samples; all blood analyses
being done at the University laboratory on the day of
blood collection. For lipid measurement, LDL-C, HDL-C,
TC, and TG were measured using HUMAN kit, Germany.
The MS was defined according to ATPIII definition.
Chlorpromazine equivalents (CPZeq): Total CPZeq
was constructed by calculating a total daily dose of each
Table 1 General characteristics of the study sample
Variable











250 (100%) 182 (73.8%) 68 (27.2%)
Age (years) 41.9 ± 11.8 42.5 ± 11.5 40.3 ± 12.4 0.2a
d = 0.18 −1.3
Education 0.4b
≤ School education 213 (85.2%) 153 (84.1) 60 (88.2) 1.4 (0.62 – 3.3)
College education 37 (14.8%) 29 (15.9) 8 (11.8) d = 0.18 0.68
Marital Status <0.01 b
Married 138 (55.2%) 88 (48.4) 50 (73.5) 3 (1.6 – 5.5)
Single/Divorced 112 (44.8%) 94 (51.6) 18 (26.5) d = 0.61 12.7
Smoker < 0.01 b
Yes 153 (61.2%) 55 (80.9) 42 (23.1) 14.1 (7 – 28.3)
No 97 (38.8%) 13 (19.1) 140 (76.9) d = 1.46 69.66
Occupation 0.1 b
Not working 219 (87.6%) 156 (85.7) 63 (92.6) 2.1 (0.8 – 5.7)
Working 31 (12.4%) 26 (14.3) 5 (7.4) d = 0.41 2.2
Duration of psychiatric illness 15.8 ± 9.3 16.2 ± 9.0 14.8 ± 9.9 0.3 a
d = 0.15 −1.01
Waist Circumference < 0.01 b
Normal 137 (54.4) 124 (68.1%) 12 (17.6%) 0.1 (0.05 – 0.2)
Above Normal 114 (45.6%) 58 (31.9%) 56 (82.4%) d = −1.27 50.86
Systolic Blood Pressure 124.2 ±14.4 125.1 ± 14.1 121.8 ± 15 0.1 a −1.6
d = 0.23
Diastolic Blood Pressure 75.5 ± 10.8 76.4 ± 10.2 73 ± 12.1 0.04 a −2.0
d = 0.3
Triglycerides 193.2 ± 180.2 187.3 ± 125.4 208.8 ± 279 0.5 a 0.6
d = −0.1
HDL-C 44.9 ± 10.9 43.8 ± 11 46.4 ± 10.6 0.1 a 1.7
d = −0.24
FPG 99.5 ± 47.5 96.6 ± 45.3 107.3 ± 52.6 0.1 a 1.5
d = −0.2
CPZeq 436.9 ± 275.6 455.6 ± 283.7 386.8 ± 247.7 0.07 a −1.9
d = 0.3
Olanzapine/Clozapine 0.9 b
Yes 30 (12) 22 (12.1) 8 (11.8) 1.2 (0.6 – 2.3) 0.18
No 220 (88) 160 (87.9) 60 (88.2) d = 0.1
Drug regimen 0.1 b
Monotherapy 124 (49.6) 85 (46.7) 39 (57.4) 1.5 (0.9 – 2.7) 2.2
Combination therapy 126 (50.4) 97 (53.3) 29 (42.6) d = 0.22
Abbreviations: SD, Standard deviation; OR, Odds ratio; CI, confidence interval; HDL-C, High-density lipoprotein cholesterol; FPG, Fasting plasma glucose; CPZeq,
Chlorpromazine equivalents.
a Statistical significance of differences estimated with the independent Student’s t test.
b Statistical significance of differences estimated with the Chi square test.
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Table 2 Prevalence of metabolic abnormalities using ATP-






0 22 (8.8%) 21(11.5%) 1 (1.5%)
1 56 (22.4%) 46 (25.3%) 10 (14.7%)
2 63 (25.2%) 44 (24.2%) 19 (27.9%)
3 52 (20.8%) 38 (20.9%) 14 (20.6%)
4 47 (18.8%) 28 (15.4%) 19 (27.9%)
5 10 (4%) 5 (2.7%) 5 (7.4%)
MS≥ 3 109 (43.6%) 71 (39%) 38 (55.9%)
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verted antipsychotic-specific CPZeq amount is added to
arrive at a total dose. The daily dose of antipsychotic
medication prescribed to each patient was converted to
milligram equivalents of chlorpromazine according to
conversion factors derived from the literature [32-34].
The operational definition of antipsychotic combi-
nation is the use of two or more antipsychotic drugs
while that of monotherapy is the use of one anti-
psychotic drug.
Statistical analysis
Descriptive statistics for all study variables were com-
puted. These descriptive statistics included frequencies
and percentages for all categorical variables in addition to
means, standard deviations and ranges for all normally
distributed continuous variables while median and inter
quartile range was used for continuous variables that were
not normally distributed. Differences between groups were
carried out using independent sample t test for continuous
variable while Chi-square test was used for categorical
variables. The size effect for continuous variables was
expressed as Cohen’s d value using the on line calculator
(http://www.uccs.edu/~lbecker/). For categorical variables,
the size effect was calculated as OR and then converted to
Cohen’s d value based on mathematical equation present
in literature [35]. Univariate analysis was carried out using
the Binary logistic regression while multiple logistic
regression was carried out on variables that showed
significance in univariate analysis. In both univariate and
multiple logistic regression, the presence of MS was used
as the dependent categorical variable. All statistical
analyses were conducted using Statistical Package for
Social Sciences SPSS (PASW version 18.0; IBM, Somers,
NY) statistical packages for Windows. The conventional 5
percent significance level was used throughout the study.
Results
General descriptive data
A total of 250 patients diagnosed with schizophrenia
were recruited for this study. Mean age of the patients
was 41.9 ± 11.8 [95% CI: 40.5 – 43.4] years. No signifi-
cant difference in age was found between male and
female patients (40.3 ± 12.4 for females versus 42.5 ±
11.5 years for males; p = 0.2). The median duration of
the psychiatric illness was 15 (Q1 – Q3: 9 – 20) years.
The majority (194, 77.6%) of the patients were using
first-generation antipsychotic (FGA) while 33 (13.2%)
were using second-generation antipsychotics (SGA) and
23 (9.2%) were using both FGA and SGA. Table 1 shows
the general characteristics of the sample stratified with
gender.
The most common antipsychotic medication used by
the patients was chloropromazine tablet (128; 31.5%),followed by fluphenazine IM depot injection (125; 30.8%),
haloperidol tablet (74; 18.2%), clozapine (35, 8.6%), olanza-
pine (15, 3.7%), haloperidol decanoate (11, 2.7%), risperi-
done (8, 2%), trifluperazine (7, 1.7%), thioridazine (1, 0.2%)
and zuclopenthixol (2, 0.5%). Table 1 shows the demo-
graphic and clinical characteristics of the participants.
Prevalence of metabolic syndrome
According to the ATP-III A criteria: 109 (43.6%) patients
met the criteria for the syndrome (3 or more MS criteria)
while141 (56.4%) patients did not meet the full criteria for
the syndrome (2 or less MS criteria); (Table 2). On average,
the study patients had 2.3 ± 1.3 metabolic abnormalities.
Table 3 displays the distribution of metabolic components
as defined by ATP-III A criteria among the recruited
patients. Among males, high TG was the most common
metabolic component while abdominal obesity was the
most common among females (Table 4). High FPG was the
least common metabolic dysregulation in both genders.
The frequency of abdominal obesity (WC) and low
HDL-C in female patients was significantly higher than
that in males. The overall prevalence of MS was 43.6%.
Female patients had higher MS prevalence than male
patients.
Univariate analysis and logistic regression
Univariate analysis (Table 3) shows that cases with MS
were significantly older, being females, having longer
duration of the illness, smokers, had higher systolic and
diastolic BP, higher waist circumference, higher TG,
FPG, and lower HDL compared to cases without MS.
Borderline significance was found between cases with
and without MS with regard to using depot anti-
psychotic medications and LDL level. On the other hand
there was no significant difference between both groups
with regard to other variables. Multiple logistic regres-
sion (Table 3) which included significant variables in
univariate analysis indicated that SBP, TG, FPG, HDL
and WC were significantly associated with MS cases.
Table 3 Univariate and logistic regression analysis of metabolic syndrome of 250 patients
Variable With MS N
(%) or Mean ± SD
Without MS N (%)





Age (years) 45.1 ± 10.4 39.5 ± 12.2 1.04 (1.02 –1.07) 0.98 (0.93 – 1.03)
Gender
Female 38 (55.9%) 30 (44.1%) 2 (1.1 – 3.5) 1.91 (0.64 – 5.69)
Male 71 (39%) 111 (61%)
Duration
< 10 years 90 (42.3%) 123 (57.7%) 2.2 (1.3 – 3.8) 1.94 (0.62 – 6.01)
>10 years 19 (51.4) 18 (48.6%)
Smoking
Yes 55 (35.1%) 98 (64.9%) 2.2 (1.3 – 3.8) 2.16 (0.82 – 5.69)
No 54 (55.7%) 43 (44.3%)
Marital status
Married 53 (47.3%) 59 (52.7%) 0.76 (0.46 – 1.25) –
Single 56 (40.6%) 82 (59.4%)
Education
< 12 years 90 (42.3%) 123 (57.7%) 1.4 (0.7 – 2.9) –
>12 years 19 (51.4%) 18 (48.6%)
Occupation
Employed 12 (38.7%) 19 (61.3%) 0.8 (0.36 – 1.7) –
Unemployed 97 (44.3%) 122 (55.7%)
Family history of DM
Yes 52 (46.4%) 60 (53.6%) 1.2(0.75 – 2.04) –
No 57 (41.3%) 81 (57.7%)
CPZeq (mg) 432 ± 284.3 440.6 ± 269.7 1(0.9 – 1) –
Therapeutic Regimen
Monotherapy 53 (42.7%) 71 (57.3%) 1.07(0.65 – 1.8) –
Combination 56 (44.4%) 70 (55.6%)
Depot antipsychotic
Yes 68 (49.3) 70 (50.7%) 1.7 (1.01 – 2.8) 1.74 (0.73 – 4.14)
No 41 (36.6%) 71 (63.4%)
Olanzpine/Clozapine
Yes 10 (33.3%) 20 (66.7%) 0.61 (0.3 – 1.4) –
No 99 (45%) 121 (55%)
WC (cm) 105.1 ± 13.2 92.3 ± 10.7 1.1 (1.07 – 1.1) 1.09 (1.05 – 1.13)
Systolic BP (mmHg) 131.1 ± 12.9 118.9 ± 13.2 1.07 (1.05 – 1.1) 1.11 (1.07 – 1.16)
Diastolic BP (mmHg) 78.4 ± 10.1 73.2 ± 10.9 1.05 (1.02 – 1.07) 0.96 (0.92 – 1.01)
TG (mg/dl) 256.4 ± 224.6 144.3 ± 115.4 1 (1 – 1) 1.01 (1.0 – 1.01)
HDL (mg/dl) 42.4 ± 11.8 46.2 ± 9.9 0.96 (0.94 – 0.99) 0.95 (0.91 – 1.00)
LDL (mg/dl) 121.7 ± 36.8 112.1 ± 39.1 1 (1 – 1.01)
FPG (mg/dl) 120.5 ± 64.5 83.3 ± 13.9 1.05 (1.03 – 1.07) 1.06 (1.03 - 1.09)
Abbreviations: SD, Standard deviation; OR, Odds ratio; CI, confidence interval; MS, Metabolic syndrome; DM, diabetes mellitus; WC, Waist Circumference; HDL, High-
density lipoprotein; LDL, low-density lipoprotein; BP, Blood pressure; TG, triglyceride; FPG, Fasting plasma glucose; CPZeq, Chlorpromazine equivalents.
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Table 4 Prevalence of metabolic dysregulations in patients with schizophrenia
MS ATP-III A All Frequency (%) Male Female OR (95% CI) and d (Cohen’s value) P Chi-Square value
WC (M > 102 cm; F > 88 cm) 114 (45.6%) 58 (31.9%) 56 (82.4%) 0.1 (0.05 – 0.2) d = −1.3 <0.01 50.9
FPG (≥100 mg/dL) 80 (32%) 52 (28.6%) 28 (41.2%) 0.6 (0.3 – 1.02) d = −0.28 0.06 3.6
HDL (M < 40 mg/dl; F < 50 mg/dl) 130 (52%) 87 (47.8%) 43 (63.2%) 0.53 (0.3 – 0.94) d = −0.35 0.03 4.7
BP (≥ 130/85 mmHg) 129 (51.6%) 92 (50.5%) 31 (45.6%) 1.2 (0.68 – 2.1) d = 0.1 0.55 0.35
TG (> 150 mg/dl) 123 (49.2%) 96 (52.7%) 33 (48.5%) 1.2 (0.7 – 2.1) d = 0.1 0.5 0.49
Abbreviations: MS, Metabolic syndrome; ATP-III, Adult Treatment Panel III; OR, Odds ratio; CI, confidence interval; WC, Waist Circumference; M, Male; F, Female; HDL,
High-density lipoprotein; FPG, Fasting plasma glucose; BP, Blood pressure; TG, triglyceride.
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In this study we investigated prevalence of MS among a
sample of Arab patients with schizophrenia. We esti-
mated that approximately 44% of the study sample has
the metabolic syndrome. The high prevalence of the
metabolic syndrome in the present study has several
clinical implications. First, there is a crucial need to
develop methods, including physical activity and nutri-
tion, to control metabolic abnormalities among schizo-
phrenic patients. Second, education and training are
needed to ensure that mental healthcare workers have
the knowledge and skills necessary to identify schizo-
phrenic patients with the metabolic syndrome. Third,
close collaboration between mental healthcare workers
and other physicians is needed to establish better health-
care for patients with schizophrenia. Finally, use of anti-
psychotics with lesser metabolic side effects is needed in
patients at risk of developing MS.
Even though there is a considerable variation in meth-
odology and criteria among published studies, the MS
prevalence in our study was within the range of prior
reports published regionally and worldwide [36-42].
Studies about prevalence rate of MS obtained in the
Arab world are few. A study carried out among 63
patients to determine the risk factors of metabolic
syndrome in a sample of Egyptian patients with schizo-
phrenia using the IDF criteria found that twenty four
patients (38.09%) met the criteria for MS [42]. Another
study carried out among 220 UAE psychiatric inpatients
using the NCEP ATP III criteria found that the preva-
lence of metabolic syndrome was about 48.1% [43].
Our study showed that female patients had higher risk
of having MS, which is a common finding in previous
studies [36,38-41]. In a between gender comparison, a
higher proportion of central obesity and low HDL-C in
female patients with schizophrenia in this study was
consistent with observations in the literature [38-40].
We did not find a relationship between the presence
of MS and types of antipsychotic drug. The relationship
between antipsychotic drugs and risk of developing MS
has remained divergent in the literature [37,41,44,45].
Our results have found no significant difference in the
antipsychotic dose measured as CPZeq or antipsychoticregimen and the presence or absence of MS. A study has
reported that those receiving a combination of SGA and
FGA had a higher risk of developing MS [46]. Another
study showed no difference on MS profiles between
patients using FGA, SGA, or combination therapy [47].
Despite the clear evidence that antipsychotic drugs are
implicated in metabolic disease in patients with schizo-
phrenia, there is increasing evidence that schizophrenia
itself is an independent risk factor [48,49].
It is well known that MS increases the risk of develo-
ping cardiovascular disease (CVD) and diabetes. A study
has shown that metabolic syndrome accounts for up to
one third of CVD in men and approximately half of new
Type II diabetes mellitus over 8 years of follow-up [50].
It was suggested that CVD risk factors have an additive
effect on risk for CVD, and the same statement is gene-
rally true for metabolic syndrome traits and risk for
CVD and Type II DM [51]. However, Framingham
model remains the most commonly validated risk model
for CVD [52].
This study has three limitations. First, we enrolled
subjects with stable schizophrenia state while acutely ill
and more chronically sedentary patients were not
included in this study which affects the generalization
of the results. Second, the duration of antipsychotic
drug use in this cross-sectional design was not obtained.
Switching of antipsychotics is common among psychi-
atric patients. So the prevalence of MS between types of
antipsychotics did not show significant difference.
Third, factors that potentially affect the development of
MS, such as lifestyle or genetic variations were not
investigated.Conclusions
In conclusion, this study indicates that the metabolic
syndrome is prevalent in Arab patients with schizophre-
nia. Physicians treating patients with schizophrenia are
recommended to monitor the components in the meta-
bolic syndrome to identify those subjects with an
increased risk for cardiovascular disorders. In addition,
patient education and proper selection of antipsychotic
agents are needed.
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